During editorial follow-up, members of the PLOS One Editorial Board noted that the study design of [1] does not test causality as analysis in cells or organisms with targeted deletions in the pathway needed to abrogate the effect are not included in [1], and, as such, statements regarding causal relationships between NF-κB inhibition and the beneficial effects of compound K on DSS-induced colitis are speculative. Here, NFKB1 is linked to colitis.